MedTrace Logo

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

NCT00136539 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-02-18

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.

Conditions

Interventions

DRUG

Herceptin

Given intravenously once weekly for 12 weeks prior to surgery.

DRUG

Taxol

Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.

DRUG

Adriamycin

Given every three weeks for 12 weeks after surgery.

DRUG

Cytoxan

Given every three weeks for 12 weeks after surgery.

Sponsors & Collaborators

Principal Investigators

  • Harold Burstein, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-31
Primary Completion
2006-11-30
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00136539 on ClinicalTrials.gov